Pulmonology CME

  • FEATURED
    FREE GIFT CARD

    BoardVitals Pulmonary and Critical Care Medicine CME Pro Plus w/ Bonus $2,500 Amazon or Visa Prepaid Card

    Complete your CME and MOC Requirements Online with the BoardVitals Online CME + MOC Pulmonary and Critical Care Medicine Self-Assessment Activity with up to a Bonus $2,500 Amazon or Visa Prepaid Card. Answer board-style questions and cases related to your specialty and earn credits fast!

    Key features of BoardVitals Online CME + MOC Pulmonary and Critical Care Medicine Self-Assessment Activity include:

    • Thousands of board-style questions and cases with evidence-based explanations for review
    • Aligned with the MOC / Recertification exam content for each specialty board
    • Answer questions to earn credits and correct wrong answers as you go
    • Earn up to 100 AMA PRA Category 1 CreditsTM and MOC credits (varies by specialty)
    • Up to 24-month access + a bonus $2,500 Amazon or Visa Prepaid Card (your choice!)

    Target Audience: Physicians focusing on Pulmonary or Critical Care Medicine

    See full details chevron_right
    • Cost: Varies
    • Credit hours: 40
    • CME credits awarded by: University of Nebraska Medical Center
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • BoardVitals Pulmonary and Critical Care Medicine CME Board Review

    The BoardVitals Pulmonary and Critical Care Medicine CME Review offers clinicians 40 AMA PRA Category 1 CreditsTM, 40 ABIM MOC points, and over 600 Pulmonary and Critical Care Medicine board review questions. The questions cover key topics including infections, pulmonary disease, and neurologic disorders. This question bank will assist clinicians with Pulmonary and Critical Care Medicine certification and recertification.

    The BoardVitals Pulmonary and Critical Care Medicine CME Review also features:

    • Quick and Convenient CME
    • Computer, phone, and tablet access
    • Constantly updated up-to-date questions
    • Questions that are targeted specifically to the exam
    • Online CME tracker
    • 100% Pass Guarantee
    • Statistical comparison to other Pulmonary and Critical Care Medicine test-takers (Nationally)

     

    After completing this activity, you should be able to:

    • Provide guideline and knowledge-based approaches to critical care situations involving the management of complex cardiac and pulmonary disease
    • Evaluate and manage common and uncommon mechanisms and functions of the pulmonary system
    • Investigate the underlying pathophysiology of pulmonary disease and basic science knowledge

     

    Target Audience: Clinicians focusing on Pulmonary and Critical Care Medicine

    See full details chevron_right
    • Cost: $599
    • Credit hours: 40
    • CME credits awarded by: BoardVitals
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • 30% OFF W/ CODE: CME30

    Oakstone CME Brigham Board Review in Pulmonary Medicine

    Continuing Medical Education: Advances in Pulmonary Medicine

    Get state-of-the-art information on major areas in pulmonary medicine while you prep for exams with The Brigham Board Review in Pulmonary Medicine online CME course. Learn how to put optimal therapeutic strategies into practice while reviewing the latest techniques for treating respiratory infections, lung diseases, interstitial disorders, vascular diseases, and more. This pulmonary medicine board review you will help you to:

    • Understand clinical problems reflected in the ABIM pulmonary disease subspecialty board examination
    • Summarize major areas in pulmonary medicine, including respiratory physiology, genetics, and cell and molecular biology
    • Evaluate pulmonary function testing, fundamental pulmonary imaging, and cardiopulmonary exercise testing

    Learning Objectives

    At the conclusion of this activity, the participant will be able to:

    • Apply current/recommended pulmonary guidelines in clinical practice
    • Perform differential diagnosis of complex clinical presentations related to pulmonary disorders
    • Identify/apply current therapeutic options for specific pulmonary disorders
    • Evaluate and interpret up-to-date literature relevant to clinical practice in pulmonary medicine
    • Illustrate knowledge of pathophysiology as it applies to management of pulmonary disorders
    • Apply knowledge gained to the ABIM certification/recertification pulmonary examinations

    Intended Audience

    This educational activity was designed for fellows/trainees and practicing pulmonary specialists (MDs) and other professional affiliates (internists with an interest in Pulmonology) who are preparing to take ABIM Board Review or Recertification Examinations or who seek CME activities to improve patient care in the area of Pulmonary Medicine.

    See full details chevron_right
    • Cost: $895
    • Credit hours: 30.75
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Format: On-Demand Online, Online Video, Online Audio, Audio CD
    • Material last updated: April 24, 2020
    • Expiration of CME credit: April 24, 2023
  • MedCram 3 year All Access CME Pass

    Medical videos & lectures explained clearly by world-class instructors.

    Memorable illustrations, clinical scenarios, and passionate instructors set MedCram apart from other online medical lectures.

    We prioritize the most important clinically relevant and practical information for clinical practice.

    Understanding medicine has never been so simplified.

    See full details chevron_right
    • Cost: $495
    • Credit hours: 46.75
    • CME credits awarded by: ACCME
    • Format: Medical education videos available on demand
    • Material last updated: Continuously Updated
  • FEATURED

    BoardVitals Pulmonary Disease and Critical Care Medicine Board Review Question Bank

    Pass the Pulmonary and Critical Care certification examinations with the BoardVitals Pulmonary Disease and Critical Care Medicine Board Review Question Bank. Targeted to the ABIM Pulmonary Disease Certification Exam as well as the ABIM/ABEM Critical Care Medicine Certification Exam, this board review question bank will help you pass your boards.

    BoardVitals Pulmonary Disease and Critical Care Medicine Board Review Question Bank features:
    • 700 Pulmonary Disease and Critical Care Medicine practice questions developed by top specialists dual certified in Pulmonary and Critical Care Medicine
    • Detailed rationales for every exam question including explanations for incorrect responses
    • Customize your practice by category to target weaknesses
    • Earn up to 40 CME Credits and 40 ABIM MOC points with optional payment of $200
    • 24/7 access from any computer, tablet or smartphone
    • 100% Pass Guarantee

    Target Audience:
    This program is targeted to Pulmonary Disease specialists and Critical Care Medicine specialists preparing for specialty board exams.

    See full details chevron_right
    • Cost: $129
    • Credit hours: 40
    • CME credits awarded by: University of Nebraska Medical Center
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FREE

    Frontiers in the treatment of systemic sclerosis interstitial lung disease: therapeutic updates and best practices

    In this online CME self-learning program: Systemic sclerosis (SSc) is a rare connective tissue disease that affects between eight and 56 people per million per year and up to 341 people per million total in the U.S., of whom around 70% will experience interstitial lung disease (ILD). The disease is characterized by a progressive course of scarring to the blood vessels underlying the skin, connective tissue, joints, and organs. The pathology of SSc remains to be fully elucidated, but different immunologic and genetic pathways have been explored as potential precipitating factors for SSc. Based on what is known, SSc-ILD may be summarized into three steps: 1) continuous injury to endothelial cells, 2) activation of innate and adaptive immunity, 3) recruitment and activation of fibroblasts. Early diagnosis is crucial for preservation and survival of major organs. Lung fibrosis is considered irreversible, and if the disease has progressed far beyond repair, lung transplantation is considered. Therefore, early detection is paramount in order for patients to preserve their lung function.

    Target Audience:

    The following HCPs: pulmonologists, rheumatologists, radiologists, primary care physicians, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with SSc-ILD.

    By the end of the session the participant will be able to:

    • Define the clinical features of systemic sclerosis
    • Discuss current understanding of the biology of systemic sclerosis
    • Define clinical phenotypes of systemic sclerosis
    • Explore pulmonary manifestations of systemic sclerosis
    • Understand the approach to diagnosis of systemic sclerosis interstitial lung disease and other pulmonary manifestations
    • See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/08/2020
    • Expiration of CME credit: 10/08/2022
  • FREE

    Cystic fibrosis: Therapeutic updates and optimizing treatment

    Cystic Fibrosis (CF) is a genetic disease that affects nearly 70,000 people worldwide with more than 90% of patients diagnosed of Caucasian descent and a median lifetime survival remains a mere 43.6 years. CF is caused by an autosomal recessive mutation in the CF transmembrane regulator (CFTR) gene, which controls the other chloride and sodium channels at the cell surface and is found in the lungs, liver, pancreas, intestine, sweat duct, and epididymis. The primary organs in which the disease manifests clinically are the pancreas, leading to malabsorption of nutrients, and the lungs due to the accumulation of thick, sticky mucous that contributes to airway obstruction. CF causes several clinical complications, including recurrent pulmonary infections, nasal polyps, CF-related diabetes, fat-soluble vitamin deficiencies, acid reflux, and liver failure.

    Target Audience:

    The following HCPs: pulmonologists, pediatricians, gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with CF.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of CF such that it might inform treatment mechanisms.
    • Identify the currently available and emerging pharmacotherapeutic treatments for the management of CF and apply them to patient cases using evidence-based medicine.
    • Describe newly approved and investigational therapies in development for CF.
    • Evaluate an ongoing treatment plan for a specific patient with CF to optimize safety and efficacy, suggesting modifications for improvement, including the management of complications.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/18/2020
    • Expiration of CME credit: 07/18/2022
  • FREE

    Alpha-1 antitrypsin deficiency (AATD): Optimizing pharmacotherapeutic management strategies

    Alpha 1-antitrypsin deficiency (AATD), characterized by low serum levels of the serine protease inhibitor alpha-1 antitrypsin (AAT), is a genetic disorder resulting in destruction of lung structures. Reduced levels of AAT result in overactivity of neutrophil elastase, which destroys connective tissue within the lung and causes degradation of alveoli, reduced pulmonary elastic recoil, and airflow. Breakdown of the alveoli eventually manifest as emphysema or other forms of chronic lung disease, including chronic obstructive lung disease (COPD). Other complications associated with AATD include liver disease, panniculitis, and vasculitis. The most common cause of death in patients with severe AATD is respiratory failure, which accounts for 45 to 72% of deaths. Smoking, occupational hazards such as firefighting, and high levels of cumulative exposure to pollution accelerate the rate of lung function decline in people with AATD. AATD is estimated to affect one out of every 2,000 to 5,000 individuals, mainly of North European or Iberian ancestry, with a global prevalence of over 3.4 million affected individuals.

    Target Audience:

    The following healthcare professionals: pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.

    By the end of the session the participant will be able to:

    • Summarize the present state of awareness of AATD among healthcare professionals and its attendant impact on patient care.
    • Describe the best time to test a patient for AATD and whether to conduct a family screening.
    • Apply best treatment practices to patients with AATD in various clinical scenarios.
    • Describe the challenges associated with the optimal diagnosis and treatment of AATD.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/26/2020
    • Expiration of CME credit: 07/26/2022
  • FREE

    Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies

    Interstitial lung disease (ILD) is a collective term used to categorize more than 200 different types of diseases that affect the alveolar structures, the pulmonary interstitium, and small airways.

    After completing Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies you will be able to:

    • Describe the pathophysiology of and risk factors for ILD-PF such that it might inform treatment mechanisms and strategies
    • Identify signs and symptoms of ILD-PF (e.g., rheumatoid arthritis, chronic hypersensitivity pneumonitis, unclassified ILD)
    • Describe the prevalence, morbidity, and mortality, burden of illness associated with ILD-PF and, conversely, the benefits associated with early identification and treatment
    • Describe current treatment standards and monitoring parameters (HRCT, PFTs) of ILD-PF, including developments in clinical research and treatment guidelines, and apply them to patient cases
    • Discuss ways to improve clinician communication with their patients, including disease education

     

    Target Audience: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with ILD-Pf.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: January 27, 2019
    • Expiration of CME credit: January 27, 2021
  • FREE

    An Update on Fixed-Dose LAMA/LABA Inhalers in COPD

    An Update on Fixed-Dose LAMA/LABA Inhalers in COPD consists of written presentations by 4 experts on the use of Fixed-Dose Inhalers in COPD.

    Upon completion of An Update on Fixed-Dose LAMA/LABA Inhalers in COPD, you should be able to:
    • Evaluate key efficacy data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
    • Evaluate key safety data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
    • Apply information on the efficacy and safety of new/emerging LAMA/LABA inhalers in COPD to specific clinical scenarios.

    Target Audiences:
    This program is intended for health care professionals who treat and manage patients with COPD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: The France Foundation
    • Format: On-Demand Online
    • Material last updated: September 30, 2016
    • Expiration of CME credit: September 29, 2017